Clinical Trial Update: Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tucatinib in combination with trastuzumab and TAS-102 for HER2-positive metastatic colorectal cancer in molecularly selected patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• TAS-102 (Lonsurf) (trifluridine/tipiracil)
• Trastuzumab (Herceptin) (trastuzumab)
• Tucatinib (Tukysa) (tucatinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: WITHDRAWN